Literature DB >> 24669198

Mutations in PRSS1 put into perspective.

Philipp G Sand1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24669198      PMCID: PMC3964445          DOI: 10.7150/ijms.7613

Source DB:  PubMed          Journal:  Int J Med Sci        ISSN: 1449-1907            Impact factor:   3.738


× No keyword cloud information.
I have read with interest the recent paper by Liu and Zhang 1 on the putative association of the PRSS1 gene with pancreatitis. In their article, the authors claim a highly significant association based on a meta-analysis of seven previous case-control studies. Their methodological approach, however, warrants a cautionary comment. To assess the impact of PRSS1 mutations, the authors have conceptualized the entire gene as a risk-modifier. Thus instead of counting carriers of a single variant, all carriers of at least one variant were supposedly grouped together. Clearly, a metaanalysis in this fashion is quite uninformative. A gene is made up of numerous DNA base pairs of which some may augment the risk for disease, while others may act in the opposite direction and yet others act neutrally with regard to a given phenotype. Similar risk-enhancing effects of genetic variants within the same gene imply that linkage disequilibrium between these markers is very high. This does not apply to PRSS1 mutations and therefore no rationale exists for indiscriminate pooling of mutations or polymorphisms (i.e. N29I, N29T, L104P, R116C, A121T, R122H, R122C, T137M, C139S, D162D, G208A) across the gene. When data are re-analyzed for the two most commonly examined mutations (N29I and R122H) assuming a dominant mode of inheritance for the minor allele under a random effects model, and applying a Bonferroni correction, the overall net effect remains significant for R122H (p= .03) but is only borderline significant for N29I (p= .05, Fig. 1). When the same analysis is restricted to European populations, significance is lost for N29I (p> .09). Moreover, the true effect of PRSS1 variants is likely obscured by pooling of all age-groups, pooling of acute and chronic phenotypes, pooling of early and late onset phenotypes, plus pooling of primary and secondary forms of pancreatitis. Future analyses will need to reassess in more detail the association with PRSS1 for subjects with respect to high and low genetic load.
Fig 1

Forest plots for metaanalyses of all studies addressing PRSS1 carrier status for N29I (top) and R122H (bottom).

  5 in total

1.  Genetic mutations in a Spanish population with chronic pancreatitis.

Authors:  Josefina Mora; Laia Comas; Elia Ripoll; Patricia Gonçalves; Josep M Queraltó; Francesc González-Sastre; Antoni Farré
Journal:  Pancreatology       Date:  2009-08-04       Impact factor: 3.996

2.  High incidence of PRSS1 and SPINK1 mutations in Korean children with acute recurrent and chronic pancreatitis.

Authors:  Yeoun Joo Lee; Kyung Mo Kim; Jin Ho Choi; Beom Hee Lee; Gu-Hwan Kim; Han-Wook Yoo
Journal:  J Pediatr Gastroenterol Nutr       Date:  2011-04       Impact factor: 2.839

3.  Analysis of CFTR, SPINK1, PRSS1 and AAT mutations in children with acute or chronic pancreatitis.

Authors:  Agnieszka Sobczyńska-Tomaszewska; Daniel Bak; Beata Oralewska; Grzegorz Oracz; Aleksandra Norek; Kamila Czerska; Tadeusz Mazurczak; Mikołaj Teisseyre; Jerzy Socha; Marek Zagulski; Jerzy Bal
Journal:  J Pediatr Gastroenterol Nutr       Date:  2006-09       Impact factor: 2.839

4.  A comprehensive study indicates PRSS1 gene is significantly associated with pancreatitis.

Authors:  Jie Liu; Hong-xin Zhang
Journal:  Int J Med Sci       Date:  2013-06-13       Impact factor: 3.738

5.  The prevalence of cationic trypsinogen (PRSS1) and serine protease inhibitor, Kazal type 1 (SPINK1) gene mutations in Polish patients with alcoholic and idiopathic chronic pancreatitis.

Authors:  Anita Gasiorowska; Renata Talar-Wojnarowska; Leszek Czupryniak; Beata Smolarz; Hanna Romanowicz-Makowska; Andrzej Kulig; Ewa Malecka-Panas
Journal:  Dig Dis Sci       Date:  2010-07-30       Impact factor: 3.199

  5 in total
  1 in total

1.  Silencing PRSS1 suppresses the growth and proliferation of gastric carcinoma cells via the ERK pathway.

Authors:  Dongmei Ye; Yuxuan Li; Heliang Zhang; Zhiwei Zhou; Yujie Tang; Peng Wu; Qiang Zhao; Zhiwei Zhang
Journal:  Int J Biol Sci       Date:  2021-03-01       Impact factor: 6.580

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.